drugset / Trial / NCT04637503
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in patients with relapsed and refractory neuroblastoma (NB). Another goal of the study is to understand the function of the multi-CAR-T cells and their persistency in the patients.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GD2, PSMA and CD276 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | GD2, PSMA and CD276 CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |